Christian Kurzeder
Overview
Explore the profile of Christian Kurzeder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
105
Citations
3628
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Heidinger M, Bilfeld G, Foge N, Loesch J, Maggi N, Kiblawi R, et al.
Am J Surg
. 2025 Mar;
243:116286.
PMID: 40064063
Introduction: Oncoplastic breast surgery (OPS) with immediate symmetrization is commonly performed. However, its impact on patient-reported outcomes (PROs) remains uncertain. Methods: Patients with stage 0-III breast cancer who underwent OPS...
2.
Kurzeder C, Nguyen-Strauli B, Krol I, Ring A, Castro-Giner F, Nuesch M, et al.
Nat Med
. 2025 Jan;
PMID: 39856336
The presence of circulating tumor cell (CTC) clusters is associated with disease progression and reduced survival in a variety of cancer types. In breast cancer, preclinical studies showed that inhibitors...
3.
Harbeck N, Ciruelos E, Jerusalem G, Muller V, Niikura N, Viale G, et al.
Nat Med
. 2024 Dec;
30(12):3780.
PMID: 39653780
No abstract available.
4.
Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancer
Perez-Fidalgo A, Schmalfeldt B, George A, Gourley C, Pignata S, Lorusso D, et al.
Int J Gynecol Cancer
. 2024 Oct;
PMID: 39448084
Objectives: Maintenance therapies, including poly (ADP-ribose) polymerase (PARP) inhibitors and/or bevacizumab, have substantially improved the prognosis of patients with advanced ovarian cancer. Owing to the variability in treatment strategies across...
5.
Daster K, Hench J, Diepenbruck M, Volkmann K, Rouchon A, Palafox M, et al.
Breast Cancer Res Treat
. 2024 Oct;
209(2):389-396.
PMID: 39392573
Purpose: Most triple-negative breast cancers (TNBC) are sporadic in nature and often associated with dysfunction of the BRCA1 or BRCA2 genes. Since somatic BRCA mutations are rare in breast cancer...
6.
Harbeck N, Ciruelos E, Jerusalem G, Muller V, Niikura N, Viale G, et al.
Nat Med
. 2024 Sep;
30(12):3717-3727.
PMID: 39271844
Trastuzumab deruxtecan (T-DXd) intracranial activity has been observed in small or retrospective patient cohorts with human epidermal growth factor receptor 2-positive (HER2) advanced/metastatic breast cancer (mBC) and stable or active...
7.
Heidinger M, Loesch J, Levy J, Maggi N, Eller R, Schwab F, et al.
Eur J Surg Oncol
. 2024 Jun;
50(9):108478.
PMID: 38885597
Introduction: The American Society of Breast Surgeons (ASBrS) recently classified oncoplastic breast conserving surgery (OBCS) into two levels. The association of resection ratio during OBCS with patient-reported outcomes (PRO) is...
8.
Montagna G, Mrdutt M, Sun S, Hlavin C, Diego E, Wong S, et al.
JAMA Oncol
. 2024 Apr;
10(6):793-798.
PMID: 38662396
Importance: Data on oncological outcomes after omission of axillary lymph node dissection (ALND) in patients with breast cancer that downstages from node positive to negative with neoadjuvant chemotherapy are sparse....
9.
Grasic Kuhar C, Geiger J, Schwab F, Heinzelmann-Schwartz V, Vetter M, Weber W, et al.
Cancers (Basel)
. 2024 Apr;
16(7).
PMID: 38610984
Neoadjuvant systemic treatment (NST) is the standard treatment for HER2+, triple-negative (TN), and highly proliferative luminal HER2- early breast cancer. Pathologic complete response (pCR) after NST is associated with improved...
10.
Chiru E, Oseledchyk A, Schoetzau A, Kurzeder C, Mosimann R, Vetter M, et al.
Diagnostics (Basel)
. 2024 Jan;
14(1).
PMID: 38201405
In patients with hormone receptor positive, human epidermal receptor 2 negative (HR+/HER2-) negative breast cancer (BC), the TAILORx study showed the benefit of adding chemotherapy (CHT) to endocrine therapy (ET)...